Sorry, your browser doesn't support embedded videos.

 ISSUE 96 I July 2020

In association with

breaking

the barrier

The blood-brain barrier is notoriously difficult to penetrate, but new drugs could be up to the task

IP laws in a post Covid-19 world

Salvaging clinical trials

Targeting seasonal allergies

IP laws in a post Covid-19 world

Salvaging clinical trials

Targeting seasonal allergies
06/25/2020 10:03:06
  • Home | Breaking the Barrier
  • In this issue
  • NSF
  • Contents
  • Almac
  • News
  • VEGA Company Insight
  • VEGA Australia
  • Covid-19 executive briefing by GlobalData
  • Gilead’s remdesivir a candidate for US government stockpiling or bulk buying in
  • Covid-19’s impact on trial PROs, other endpoints can be addressed via data stratification, sensitivity analysis
  • ILC Dover
  • Vitamin D affects Covid-19 mortality
  • Clinical trial disruption due to Covid-19 has begun to slow
  • Covid-19 boosts big bio/pharma drug sales but Regeneron may be falling short
  • Mimotopes
  • The pharma industry briefing
  • Charting the ups and downs of the World Health Organization
  • Road to RECOVERY: a deep dive into the world’s largest Covid-19 drug trial
  • Salvaging clinical trials in the time of Covid-19
  • Intellectual property in the time of Covid-19
  • Molnár-Institute Company Insight
  • Molnar-Institute
  • A plight for sore eyes: the latest developments in seasonal allergy treatment
  • How research groups are tackling the problem of biologic drug delivery
  • Breaking the blood-brain barrier: neurology’s greatest challenge
  • Timeline: charting the history of immunotherapy, cancer treatment's fourth pillar
  • Creating a sure data footing for AI
  • Koehler eClinical
  • Deals in brief powered by GlobalData
  • The key list powered by GlobalData
  • Global markets and indices powered by GlobalData
  • Macro-economic indicators (1 of 2) powered by GlobalData
  • Macro-economic indicators (2 of 2) powered by GlobalData
  • Events
  • Next issue